Lazard Asset Management LLC Grows Holdings in Phibro Animal Health Corporation $PAHC

Lazard Asset Management LLC raised its stake in shares of Phibro Animal Health Corporation (NASDAQ:PAHC) by 11.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 145,811 shares of the company’s stock after acquiring an additional 14,944 shares during the quarter. Lazard Asset Management LLC owned approximately 0.36% of Phibro Animal Health worth $8,065,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. KBC Group NV bought a new position in Phibro Animal Health during the first quarter worth $29,000. 1620 Investment Advisors Inc. lifted its position in shares of Phibro Animal Health by 77.4% in the 4th quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock worth $25,000 after buying an additional 295 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in shares of Phibro Animal Health by 113.2% in the 4th quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock valued at $27,000 after buying an additional 386 shares during the period. Rothschild Investment LLC grew its position in shares of Phibro Animal Health by 2,500.0% during the 4th quarter. Rothschild Investment LLC now owns 1,040 shares of the company’s stock valued at $39,000 after buying an additional 1,000 shares during the last quarter. Finally, iSAM Funds UK Ltd bought a new position in Phibro Animal Health in the third quarter worth about $61,000. 99.34% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Phibro Animal Health news, CEO Jack Bendheim sold 7,040 shares of the stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $55.80, for a total transaction of $392,832.00. Following the completion of the transaction, the chief executive officer directly owned 67,720 shares of the company’s stock, valued at approximately $3,778,776. This trade represents a 9.42% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 50.13% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on PAHC. Citigroup dropped their price target on Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating on the stock in a research report on Thursday, May 14th. Weiss Ratings lowered Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, June 15th. Zacks Research lowered Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 21st. Finally, Wall Street Zen cut Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. One research analyst has rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $42.50.

Phibro Animal Health Trading Down 1.4%

NASDAQ:PAHC opened at $36.45 on Friday. The stock has a market cap of $1.48 billion, a price-to-earnings ratio of 15.64, a PEG ratio of 0.52 and a beta of 0.46. The company has a debt-to-equity ratio of 1.97, a quick ratio of 1.26 and a current ratio of 3.17. Phibro Animal Health Corporation has a 1 year low of $25.58 and a 1 year high of $60.08. The business has a fifty day moving average of $32.65 and a 200-day moving average of $43.20.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.76 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.04. The business had revenue of $383.54 million during the quarter, compared to the consensus estimate of $367.02 million. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. Equities analysts predict that Phibro Animal Health Corporation will post 3.08 earnings per share for the current year.

Phibro Animal Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 23rd. Stockholders of record on Wednesday, September 2nd will be issued a $0.12 dividend. The ex-dividend date is Wednesday, September 2nd. This represents a $0.48 annualized dividend and a dividend yield of 1.3%. Phibro Animal Health’s dividend payout ratio (DPR) is 20.60%.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.